A Phase II/III, Randomized, Multi-centric, Comparator-controlled Study of the Safety and Neutralizing Activity of a Human Monoclonal Antibody to Rabies (SII RMAb) Administered in Conjunction with Rabies Vaccine for Post-exposure Prophylaxis in Patients following Potential Rabies Exposure

Trial Profile

A Phase II/III, Randomized, Multi-centric, Comparator-controlled Study of the Safety and Neutralizing Activity of a Human Monoclonal Antibody to Rabies (SII RMAb) Administered in Conjunction with Rabies Vaccine for Post-exposure Prophylaxis in Patients following Potential Rabies Exposure

Completed
Phase of Trial: Phase II/III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Anti-rabies monoclonal antibody (Primary) ; Anti-rabies monoclonal antibody (Primary) ; Rabies immune globulin; Rabies immune globulin; Rabies vaccine
  • Indications Rabies
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 15 Sep 2017 Results assessing safety and neutralizing activity of a human monoclonal antibody to rabies (sii rmab) administered in conjunction with rabies vaccine for post-exposure prophylaxis in patients following potential rabies exposure, were published in the Clinical Infectious Diseases.
    • 15 Sep 2017 Status changed from recruiting to completed, according to results published in the Clinical Infectious Diseases.
    • 10 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top